Abstract: Regarding Deposited Microbial Organisms [EXPERT SOLUTION] For all deposited microbial organisms mentioned in the present patent application and which not are in collections open to the public the so-called expert solution is requested. In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample, and approved either i) by the Applicant and/or ii) by the European Patent Office, whichever applies.

Abstract: The use of probiotic bacteria that modulate expression of a number of satiety markers in the intestine and reduces fat deposition to promote an optimal body weight of a mammal is described. The invention further relates to a composition comprising such a probiotic strain of bacteria and/or a fraction of said strain and/or metabolite of said strain for the preparation of a composition for administration to a mammal for promoting an optimal body weight of a mammal.

Abstract: The present invention relates to the use of compositions comprising receptor ligands obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with lactic acid bacteria to obtain a fermented food or feed material that comprises ligands of specific adrenoreceptors and/or serotonin receptors. The fermented food or feed material is useful e.g. for reducing and/or stabilizing heart rate in a mammal. It may furthermore be used for treatment and/or relief of erectile dysfunctions and for treatment and/or relief of benign prostate hypertrophy (BPH), in a mammal.

Abstract: The invention relates to the use of a composition comprising probiotic bacteria that regulate expression of key components involved in diet-induced insulin resistance for ameliorating or preventing diet-induced insulin resistance. The use of the probiotic strain and/or a fraction of said strain and/or metabolite of said strain for the manufacture of a medicament or a food or feed product to ameliorate diet-induced insulin resistance and help to obtain optimal body weight of a mammal is disclosed.

Abstract: The use of probiotic bacteria that modulate expression of a number of satiety markers in the intestine and reduces fat deposition to promote an optimal body weight of a mammal is described. The invention further relates to a composition comprising such a probiotic strain of bacteria and/or a fraction of said strain and/or metabolite of said strain for the preparation of a composition for administration to a mammal for promoting an optimal body weight of a mammal.

Abstract: The present invention relates to the use of compositions comprising receptor ligands obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with lactic acid bacteria to obtain a fermented food or feed material that comprises ligands of specific adrenoreceptors and/or serotonin receptors. The fermented food or feed material is useful e.g. for reducing and/or stabilizing heart rate in a mammal. It may furthermore be used for treatment and/or relief of erectile dysfunctions and for treatment and/or relief of benign prostate hypertrophy (BPH), in a mammal.

Abstract: The invention relates to novel, probiotic, anti-inflammatory strains of Bifidobacterium longum, their use for treatment of diseases, and for preparation of human or pet food or pharmaceutical compositions. The strains produce high amounts of exopolysaccharides with a high content of mannose- and glucose residues. Accordingly, the invention also relates to a bacterial polysaccharide composition obtained from the strains, their use for treatment of diseases, and pharmaceutical compositions comprising such polysaccharides.

Abstract: The present invention relates to the use of compositions comprising receptor ligands obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with lactic acid bacteria to obtain a fermented food or feed material that comprises ligands of specific adrenoreceptors and/or serotonin receptors. The fermented food or feed material is useful e.g. for reducing and/or stabilizing heart rate in a mammal. It may furthermore be used for treatment and/or relief of erectile dysfunctions and for treatment and/or relief of benign prostate hypertrophy (BPH), in a mammal.

Abstract: A Lactobacillus helveticus bacterium composition for treatment of atopic dermatitis in a human.

Abstract: Use of a composition obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with a lactic acid bacterium to obtain a fermented food material which comprises active components with heart rate reducing properties for the manufacture of a product for reducing the heart rate and/or the fluctuations in the heart rate of a mammalian.

Abstract: Use of a lactic acid bacterium comprising a cell wall proteinase of around 200 kDa to prepare peptides with anti-hypertensive properties and a method for obtaining such a lactic acid bacterium.

Abstract: Use of a preparation comprising an isolated peptide selected from the group consisting of: Leu-Val (LV) (SEQ ID NO: 1) and lie-Val (IV) (SEQ ID NO: 2) for the preparation of a composition having angiotensin-converting enzyme (ACE) inhibitor effect. The peptides may e.g. be used to make a functional food with anti-hypertensive properties.

Abstract: A process for preparing peptides with anti-hypertensive properties and a process for preparing a functional food product comprising peptides with anti-hypertensive properties.

Abstract: Use of a composition obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with a lactic acid bacterium to obtain a fermented food material which comprises active components with heart rate reducing properties for the manufacture of a product for reducing the heart rate and/or the fluctuations in the heart rate of a mammalian.

Abstract: Use of a lactic acid bacterium comprising a cell wall proteinase of around 200 kDa to prepare peptides with anti-hypertensive properties and a method for obtaining such a lactic acid bacterium.